Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » News » Channel 7 reports on life changing access to Belzutifan for VHL Patients

Channel 7 reports on life changing access to Belzutifan for VHL Patients

  • January 29, 2025

Advocacy is at the heart of what NeuroEndocrine Cancer Australia (NECA) does, and stories like this showcase the powerful work happening behind the scenes to support patients across Australia.

NeuroEndocrine Cancer Australia (NECA), alongside Von Hippel-Lindau (VHL) patients Amelia and Greta, expresses immense gratitude to Channel 7 for shining a spotlight on VHL and the life-changing access to Belzutifan, the only treatment available for tumours associated with this condition.

On Tuesday, 28th January, Natarsha Belling’s interview with Amelia and Greta aired nationally during the midday news segment, followed by a comprehensive online article that delved deeper into their journey and that of others diagnosed with VHL. This dual coverage has helped raise crucial awareness about VHL and the transformative impact of Belzutifan.

NECA extends heartfelt thanks to Amelia and Greta for their patience and collaboration with NECA and Channel 7 in bringing this story to life. Their courage and willingness to share their experiences have amplified the voices of many VHL patients nationwide, reflecting NECA’s commitment to advocacy and its ongoing efforts to ensure all patients have equitable access to vital treatments and support.

Read the online article here

Share this post

Recent posts

NECA CEO Meredith Cummins is Now INCA President

February 16, 2026

Raising awareness of neuroendocrine cancer at Peninsula Bays Hospital Wellness Day

February 9, 2026

Raising Awareness for NETs on World Cancer Day in WA

February 4, 2026

Australia delivers excellent cancer care, but not equally

February 4, 2026
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousFunding announced for a dedicated Neuroendocrine Cancer McGrath Nurse in WA
NextMedia Coverage Highlights VHL Awareness and Equity in Cancer CareNext

Related Posts

NECA CEO Meredith Cummins is Now INCA President

We are proud to share that our CEO, Meredith Cummins, has been appointed President of the International Neuroendocrine Cancer Alliance (INCA). Meredith has served on

Raising awareness of neuroendocrine cancer at Peninsula Bays Hospital Wellness Day

Thank you to NET patient Kristen Leknius for hosting a neuroendocrine cancer information table at the February Peninsula Bays Hospital Wellness Day. With around 250

Raising Awareness for NETs on World Cancer Day in WA

On World Cancer Day, our WA NET Nurse, Tammy, proudly represented NeuroEndocrine Cancer Australia (NECA) at an awareness event held at Sir Charles Gardiner Hospital.

Australia delivers excellent cancer care, but not equally

Meredith Cummins is CEO of NeuroEndocrine Cancer Australia and incoming President of the International Neuroendocrine Cancer Alliance, representing patient advocacy groups worldwide. Every World Cancer

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2026 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin